MK 8507

Drug Profile

MK 8507

Alternative Names: MK-8507

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(Treatment-naive) in Germany (PO, Tablet)
  • 01 Jul 2015 Merck Sharp & Dohme completed a phase I trial in HIV-1 infections (Treatment-naive) in Germany (NCT02174159)
  • 01 Sep 2014 Phase-I clinical trials in HIV-1 infections (Treatment-naive) in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top